Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain: a Randomized Controlled Trial
The supraclavicular brachial plexus block (BPB) is a frequently used anaesthetic method for upper limb surgeries, including distal radial fracture surgery. Adding liposomal bupivacaine to BPB has shown promise in enhancing postoperative pain control. A previous randomized controlled trial demonstrated that it reduced pain scores and OBAS compared to plain bupivacaine alone, especially on postoperative day (POD) 1. Adding adjuncts to non-liposomal local anaesthetics can also enhance and prolong postoperative pain relief. The effectiveness of liposomal bupivacaine compared to adjuncts like dexamethasone and dexmedetomidine remains unclear. Since liposomal bupivacaine is more expensive, it is crucial to compare its analgesic efficacy with these alternatives. A randomized controlled trial comparing liposomal bupivacaine versus dexamethasone in the interscalene BPB for shoulder surgery found that liposomal bupivacaine resulted in statistically significantly lower pain scores and less pain interference in the Brief Pain Inventory, although the reduction was not considered clinically relevant. Its high cost may therefore limit its routine use unless specific clinical contexts where its efficacy is maximized are identified. Notably, patients with risk factors like psychological factors, preoperative pain, and prior analgesic use may benefit most from its application.
A randomized controlled trial to compare the analgesic efficacy of liposomal bupivacaine plus plain bupivacaine versus dexamethasone plus plain bupivacaine in supraclavicular BPB for patients at higher risk of poor acute pain control post distal radial fracture surgery will be conducted. Patients with severe preoperative pain, opioid use, depressive symptoms, anxiety symptoms, and/or higher energy and high-grade fracture cases will be selected. The primary outcome measured is the intensity of acute postoperative pain with movement in the first 48 hours after surgery. Important secondary outcomes include pain intensity at rest, opioid consumption, OBAS scores, chronic pain, and upper limb functionality.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Stanley S.C. Wong
- Número de teléfono: (852) 2255 3303
- Correo electrónico: wongstan@hku.hk
Ubicaciones de estudio
-
-
-
Hong Kong, Hong Kong
- Reclutamiento
- Queen Mary Hospital
-
Contacto:
- Stanley S.C. Wong
- Número de teléfono: (852) 2255 3303
- Correo electrónico: wongstan@hku.hk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- American Society of Anesthesiologist (ASA) status I-III
- Age 18-90 years old
- Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)
- Informed consent obtained
Patients identified to be at an elevated risk of suffering from poor postoperative pain control. Patients with one or more of the following risk factors:
- Severe preoperative pain: defined as worse numerical rating scale (NRS) pain score equal or higher than 6/10 with arm movements at day before surgery.
- Preoperative use of opioid: use of strong opioids such as morphine, oxycodone
- Depressive symptoms: Patient health questionnaire (PHQ-9) score of 10 or above
- Anxiety symptoms: General Anxiety Disorder (GAD-7) score of 10 or above
- Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant
Exclusion Criteria:
- Revision surgery
- Previous fractures or surgery in the affected distal radius
- Surgery involving more than the affected arm
- Cases with baseline (pre-injury) QuickDASH score worse (higher) than 10 out of 100
- Respiratory compromise (requires long term oxygen)
- History of seizures
- Pre-existing neurological disorder/deficit
- Alcohol or substance abuse
- Impaired mental state
- Local infection
- Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids
- Impaired renal function (defined as effective glomerular filtration rate < 30ml/min/1.73m2
- Impaired liver function (defined as plasma bilirubin over 34μmol/L; international normalized ratio [INR] ≥1.7, alanine aminotransferase [ALT] over 100U/L, aspartate aminotransferase [AST] over 100U/L)
- Coagulopathy (platelet count <100,000/ml and/or INR ≥ 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB
- Pregnancy
- Patient refusal for regional nerve blocks
- Patient refusal to join the clinical trial
- Patient unable/unwilling to attend post-op rehabilitation programme
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: SBPB using 10ml 0.5% plain bupivacaine with 10ml 1.33% liposomal bupivacaine (LP-BPB)
Supraclavicular brachial plexus block with 10ml 0.5% plain bupivacaine plus 10ml 1.33% liposomal bupivacaine
|
10ml 0.5% plain bupivacaine plus 10ml 1.33% liposomal bupivacaine (133mg)
|
|
Experimental: SBPB using 19ml 0.5% plain bupivacaine with 1ml (4mg) dexamethasone (D-BPB)
Supraclavicular brachial plexus block using 19ml 0.5% plain bupivacaine plus 1ml (4mg) dexamethasone
|
19ml 0.5% plain bupivacaine plus 1ml (4mg) dexamethasone
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Weighted area under curve (AUC) pain score with movement
Periodo de tiempo: The first 48 hours after surgery
|
The weighted area under curve (AUC) numerical rating scale (NRS) pain score with movement (active wrist flexion and extension) from 0-48 hours after distal radial fracture surgery.
|
The first 48 hours after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
NRS pain scores
Periodo de tiempo: Postoperative day 0-7
|
NRS pain scores both at rest and with movement will be assessed from after surgery to POD 7. (NRS scale 0-10, where 0 is no pain, and 10 is the worst possible pain)
|
Postoperative day 0-7
|
|
Overall Benefit of Analgesic Score (OBAS)
Periodo de tiempo: Postoperative day 0-7
|
Overall Benefit of Analgesic Score (OBAS) will be assessed once a day until POD 7 (range, 0 [best] to 28 [worst]).
|
Postoperative day 0-7
|
|
Acute postoperative opioid consumption
Periodo de tiempo: Postoperative day0-7
|
The daily consumption of oxycodone in the ward and after discharge will be recorded.
The dose of rescue intravenous morphine consumption in the PACU will also be recorded.
|
Postoperative day0-7
|
|
Sleep disturbance
Periodo de tiempo: Postoperative day0-7
|
Sleep disturbance due to pain will be evaluated once a day till POD 7 (0-10, where 0 represents no disturbance and 10 represents the most disturbance possible).
|
Postoperative day0-7
|
|
Quality of recovery (QoR)
Periodo de tiempo: Postoperative day0-7
|
This will be accessed using the Quality of recovery (QoR) questionnaire.
(range from 0 to 18, where 0 represent the worst quality of recovery and 18 represent the best quality of recovery)
|
Postoperative day0-7
|
|
Adverse effects related to supraclavicular BPB
Periodo de tiempo: postoperative day0-2
|
The potential side effects related to the supraclavicular BPB will be recorded.
|
postoperative day0-2
|
|
Opioid related side effects
Periodo de tiempo: postoperative day0-7
|
Opioid related side effects will be recorded.
|
postoperative day0-7
|
|
Analgesic block duration.
Periodo de tiempo: On postoperative day1
|
Time to return of pain, time to sensory resolution, time to motor resolution will be recorded on POD 1.
|
On postoperative day1
|
|
Sensory and motor assessment of the affected upper limb
Periodo de tiempo: Postoperative day0-1
|
Sensation to pin prick will be tested over the following areas: C5 (lateral shoulder), C6 (thumb), C7 (3rd finger), and C8 (4th finger) dermatomes.
Motor assessment will be done by recording grip strength and bicep contraction.
Sensation will be rated as 0-10 , where 0 represent no sensation and 10 represent normal sensation.
Motor function will be rated as 0 (paralysis), 1 (paresis), 2 (normal power).
|
Postoperative day0-1
|
|
Health related quality of life
Periodo de tiempo: Baseline and at 3, 6 and 12 weeks after surgery
|
Health related quality of life will be assessed using the SF-12v2.
Baseline scores will be obtained before surgery.
The SF-12v2 will produce two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
Both summary scores range from 0 to 100, where higher scores always indicate better physical and mental health.
|
Baseline and at 3, 6 and 12 weeks after surgery
|
|
Upper limb functional scores.
Periodo de tiempo: Baseline and at 3, 6 and 12 weeks after surgery
|
The validated Chinese versions of the Disabilities of the Arm, Shoulder, and Hand (QuickDASH) will be used to assess upper limb functional scores.
Baseline scores will be obtained before surgery.
(Range from 0 to 100, a lower score indicates a better outcome)
|
Baseline and at 3, 6 and 12 weeks after surgery
|
|
Hand grip power of normal and injured side
Periodo de tiempo: At 3, 6 and 12 weeks after surgery
|
Hand grip power of normal and injured side will be assessed (both hands).
|
At 3, 6 and 12 weeks after surgery
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Complicaciones Postoperatorias
- Procesos Patológicos
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor
- Dolor Postoperatorio
- Compuestos policíclicos
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Esteroides, fluorado
- Esparrazadienetrioles
- Dexametasona
Otros números de identificación del estudio
- UW 25-516
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .